SecBot SecBot
8-K ·Filed Nov 4, 2026

RLAY

Relay Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed12d 8h ago SEC0001193125-26-447250
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Watch for the ASH 2026 presentation on Dec 14 for updated zovegalisib data in vascular anomalies and the accompanying regulatory update, which could clarify the path to approval. Monitor enrollment progress in the ReDiscover-2 trial, now estimated to complete in mid-2027, and the planned Phase 3 trial initiation in 1L breast cancer in early 2027.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

RLAY drug pipeline →

zovegalisib

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3
Time to market
The Phase 3 ReDiscover-2 trial is expected to complete enrollment in mid-2027, meaning a potential FDA approval filing would likely follow in 2028 at the earliest.
Next catalyst
None dated

What to watchThe ASH oral presentation on December 14, 2026, is the next catalyst: updated ReInspire data in vascular anomalies and a company call with a regulatory update. Positive data could support the differentiated profile and potentially provide a path to registration, while a negative or ambiguous update would be a neutral to slightly negative outcome.

Price Chart

Loading chart...

Executive Summary

Relay Therapeutics reported Q3 2026 net loss of $81.7M ($0.37 per share), narrower than the consensus estimate of $0.40 loss per share. Cash and investments totaled $848.6M, down from $910.9M in Q2 2026, with cash runway into 2029. Key updates include estimated mid-2027 completion of the Phase 3 ReDiscover-2 trial, an upcoming ASH data and regulatory update for zovegalisib in vascular anomalies, and the appointment of Shannon Campbell as Head of Commercial.

Key Financial Metrics

EPS
−$0.37
est −$0.40 · +7.5%
Revenue
$0.00
est $1.6M · -100.0%
Rating
in line

Key Facts

  • Net loss of $81.7M ($0.37 per share) vs $74.1M ($0.43 per share) in Q3 2025
  • Cash, cash equivalents and investments of $848.6M as of Sep 30, 2026, down from $910.9M as of Jun 30, 2026
  • Cash runway expected to fund operations into 2029
  • Phase 3 ReDiscover-2 trial enrollment estimated to complete in mid-2027, about one year faster than recent benchmarks
  • Updated ReInspire data for zovegalisib in vascular anomalies to be presented at ASH on Dec 14, 2026, with a regulatory update to follow
  • Shannon Campbell appointed Head of Commercial, bringing over 30 years of experience
  • New mutant-selective TIE2 inhibitor program announced, currently in late-stage preclinical development
  • FDA granted full approval for LYRFIGTU (lirafugratinib) for cholangiocarcinoma, the first approved molecule from Relay's Dynamo platform
  • R&D expenses were $77.1M in Q3 2026 vs $68.3M in Q3 2025
  • G&A expenses were $13.1M in Q3 2026 vs $12.1M in Q3 2025

Financial Impact

Net loss of $81.7M in Q3 2026, cash burn of $62.3M from Q2 to Q3 2026

net losscash positionR&D expensesG&A expenses

Risk Factors

  • Clinical-stage biotech with no approved products generating revenue; continued operating losses
  • Cash burn rate of approximately $62M per quarter; cash runway into 2029 provides buffer but depends on trial timelines
  • Regulatory and clinical risk for zovegalisib in breast cancer and vascular anomalies
  • Dependence on successful execution of Phase 3 trials and regulatory approvals

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-447250
Document: 0001193125-26-447250-index.html0001193125-26-447250
Document: 0001193125-26-447250.txt0001193125-26-447250
8-K Data (Synthetic)0001193125-26-447250

Track record

21 reports on RLAY

Performance horizon

6 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +65.12% at T+60 after the May 19, 2026 report. 8 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $17.50 Now $17.27 −1.31% settles Feb 16
  2. Nov 16, 2026today SC 13G Neutral 4/10 Entry $17.68 Now $17.27 −2.29% settles Feb 12
  3. Nov 4, 202612d ago 8-K Neutral 4/10 Viewing No price data
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $17.00 Now $17.27 +1.59% settles Feb 3
  5. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $17.44 Now $17.27 −0.97% settles Feb 1
  6. Oct 7, 20265w ago 144 Neutral 2/10 Entry $17.41 Now $17.27 −0.80% settles Jan 5
  7. Oct 6, 20265w ago 144 Neutral 3/10 Entry $17.95 Now $17.27 −3.79% settles Jan 4
  8. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $18.89 Now $17.27 −8.58% settles Dec 4
  9. Aug 28, 202611w ago Insider Cluster Bearish 6/10 Entry $18.77 Now $17.27 +7.99% settles Nov 23
  10. Aug 18, 202612w ago Insider Cluster Bearish 5/10 Entry $20.74 to $19.72 Now $17.27 +16.73% ▲ +4.92% +4.09% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 8h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026